This is the new MLex platform. Existing customers should continue to use the existing MLex platform until migrated.
For any queries, please contact Customer Services or your Account Manager. Dismiss

Gilead, Teva should face HIV drug monopoly claims, US appeals court told

By Chris May ( November 11, 2024, 20:59 GMT | Insight) -- Gilead and Teva’s trial win in an antitrust suit over HIV treatments resulted from “a series of legal errors” that barred plaintiffs from presenting a jury with the full picture of Gilead’s “three-part monopolistic scheme,” health plans and end-payor plaintiffs told a US federal appeals court while seeking to revive their case.Gilead and Teva’s trial win in an antitrust suit over HIV treatments resulted from “a series of legal errors” that barred plaintiffs from presenting a jury with the full picture of Gilead’s “three-part monopolistic scheme,” health plans and end-payor plaintiffs told a US federal appeals court today while seeking to revive their case....

Prepare for tomorrow’s regulatory change, today

MLex identifies risk to business wherever it emerges, with specialist reporters across the globe providing exclusive news and deep-dive analysis on the proposals, probes, enforcement actions and rulings that matter to your organization and clients, now and in the longer term.


Know what others in the room don’t, with features including:

  • Daily newsletters for Antitrust, M&A, Trade, Data Privacy & Security, Technology, AI and more
  • Custom alerts on specific filters including geographies, industries, topics and companies to suit your practice needs
  • Predictive analysis from expert journalists across North America, the UK and Europe, Latin America and Asia-Pacific
  • Curated case files bringing together news, analysis and source documents in a single timeline

Experience MLex today with a 14-day free trial.

Start Free Trial

Already a subscriber? Click here to login

Related Sections